Acticor Biotech is a biopharmaceutical company, spin-off of Inserm (U1148 – Bichat Hospital, Paris, France) founded late 2013, dedicated to developing an innovative treatment in the therapy of acute ischemic stroke, a Fab directed against platelet glycoprotein GPVI.
Acticor Biotech’s CEO, Dr Gilles Avenard, is founder and former COO of Onxeo, a Euronext® company. Phase 1 is expected to start end of 2017. Acticor Biotech successfully raised 3.75 M€ until June 2016 and is preparing the next financing round of 10 M€ to go to the end of phase 2a. Positioning of the drug candidate ACT-017 is to be “first in class” antithrombotic drug without bleeding risk in the indication of first line therapy of ischemic stroke in combination or not with thrombolysis and/or mechanical thrombectomy.
